

RESEARCH ARTICLE

Open Access

Characterization of dental pulp stem/stromal cells of Huntington monkey tooth germs

Brooke R Snyder^{1,2†}, Pei-Hsun Cheng^{1,2†}, Jinjing Yang^{1,2}, Shang-Hsun Yang^{1,2}, Anderson HC Huang³ and Anthony WS Chan^{1,2*}

Abstract

Background: Dental pulp stem/stromal cells (DPSCs) are categorized as adult stem cells (ASCs) that retain multipotent differentiation capabilities. DPSCs can be isolated from individuals at any age and are considered to be true personal stem cells, making DPSCs one of the potential options for stem cell therapy. However, the properties of DPSCs from individuals with an inherited genetic disorder, such as Huntington's disease (HD), have not been fully investigated.

Results: To examine if mutant huntingtin (*htt*) protein impacts DPSC properties, we have established DPSCs from tooth germ of transgenic monkeys that expressed both mutant *htt* and green fluorescent protein (*GFP*) genes (rHD/G-DPSCs), and from a monkey that expressed only the *GFP* gene (rG-DPSCs), which served as a control. Although mutant *htt* and oligomeric *htt* aggregates were overtly present in rHD/G-DPSCs, all rHD/G-DPSCs and rG-DPSCs shared similar characteristics, including self-renewal, multipotent differentiation capabilities, expression of stemness and differentiation markers, and cell surface antigen profile.

Conclusions: Our results suggest that DPSCs from Huntington monkeys retain ASC properties. Thus DPSCs derived from individuals with genetic disorders such as HD could be a potential source of personal stem cells for therapeutic purposes.

Keywords: Adult stem cells, animal model, DPSCs, Huntington's disease, transgenic HD monkeys, cell therapy

Background

DPSCs are ASCs and were first described in 2000 [1]. DPSCs share similar characteristics with bone marrow derived mesenchymal stem/stromal cells (BMSCs) [1-4]. DPSCs have been differentiated into neuronal cells under the guidance of neurogenic factors [5-10]. Additionally, DPSCs may also be therapeutic by providing trophic support [4,11] or recruiting endogenous cells for repair [4,12].

Most studies involving ASCs are derived from healthy donors, and studies involving DPSCs have, in general, been limited. Due to the advantages of using one's own cells for therapy [13,14], plus their potential use in the central nervous system (CNS) [4-9,15,16], we are interested in characterizing DPSCs derived from individuals

with HD and determined if HD-DPSCs retain comparable stem cell properties to those derived from a healthy individual.

HD is a dominant genetic disorder caused by a mutation resulting in the expansion of polyglutamine (CAG) repeats in exon 1 of the IT15 gene encoding for *htt*. CAG repeat lengths over 39 results in pathological HD. A negative correlation has been shown between repeat length and age of onset [17] and lifespan [18]. The hallmark of HD is neurodegeneration, predominantly in the striatum and cortex [19]. Many HD patients do suffer from tooth decay; however this decay is due to medication and lack of motor skills to perform teeth maintenance procedures [20,21]. Here we have used transgenic HD monkeys [22] as a model for investigating the effect of mutant *htt* on the properties of DPSCs.

* Correspondence: awchan@emory.edu

† Contributed equally

¹Yerkes National Primate Research Center, 954 Gatewood Rd., N.E. Atlanta, GA 30329, USA

Full list of author information is available at the end of the article

Results

Establishment of DPSCs from HD monkeys

We have isolated and established DPSCs from the teeth buds of three double-transgenic HD/G monkeys (rHD11, rHD17 and rHD18) and one transgenic GFP monkey (rGFP). rHD17 and rHD18 died shortly after birth at full term. Both rHD17 and rHD18 demonstrated HD phenotypes including severe dystonia and chorea [22]. rHD11 and rGFP were miscarried monkeys, born at four months of gestation. rHD/G-DPSCs have distinctive morphology including long and spindle shaped (Figure 1A) which were similar to published reports of rBMSCs [23], rhesus monkey DPSCs (rDPSCs) [4], Chimpanzee DPSCs (ChDPSCs) [2], hBMSCs and hDPSCs [3,24,25]. There were no overt differences in cellular characteristics of DPSCs derived from different individuals. All cell lines expressed GFP (Figure 1A) and were capable of self-renewal.

Expression of stem cell specific transcription factors in rHD/G-DPSCs

To further evaluate stem cell properties of rHD/G-DPSCs with various degree of mutant htt, quantitative measurement of stemness factors (Oct-4, Nanog and Rex-1; Figure 2) was performed by Q-PCR. There was no different in the expression pattern of stemness factors between canine and molar derived DPSCs. However, variations in expression levels were observed among individuals (Figure 2). rHD17 and rHD18 have lower expression compared to rHD11 and rGFP.

Differentiation competence of rHD/GFP-DPSCs

One of the defining characteristics of ASCs is multipotent differentiation capability. All rHD/G-DPSCs were capable of differentiating into osteogenic (Figure 1B), adipogenic (Figure 1C) and chondrogenic lineages (Figure 1D), which are trademark events of ASCs [24,26] and DPSCs [3,4]. The multipotent differentiation capability of rHD/G-DPSCs and r/G-DPSCs were similar to published reports of rhesus macaques [4,23], chimpanzee [2] and humans [3,24] ASCs. Similar to previous studies, the fat droplets in DPSCs were relatively smaller and less intense than that of BMSCs [2,4].

The effect of mutant htt on the differentiation capacity of HD-DPSCs was further determined by quantitative measurement on the expression of lineage specific markers including osteopontin (osteogenic marker), lipoprotein lipase (adipogenic marker) and collagen II (chondrogenic marker) by Q-PCR (Figure 3). There was no detectable expression of lipoprotein lipase and collagen II prior to induction. On the other hand, osteopontin was expressed before induction and was increased in some of the DPSC lines after induction. Variations among cell lines were also observed (Figure 3).

Cell surface antigen profile

The expression profile of cell surface antigens is another method for determining the similarity between cell types and is often used to isolate ASCs. A total of 13 cell surface antigens were examined and compared to published reports. rHD/G-DPSCs were positive for CD29⁺, CD73⁺, CD90⁺, CD166⁺, CD59⁺, CD44⁺ and CD105⁺, all of which are BMSC markers (Table 1). However, markers specific for hematopoietic cells, including CD14, CD34, and CD45, were not detected (Table 1). rHD/G-DPSCs were also negative for CD18, CD24 and CD150 (Table 1). These results were comparable to the expression profiles of the rG-DPSCs and other higher primates (Table 1) [2,4,23,24,27]

Expression of mutant htt in rHD/G-DPSCs

In order to determine the effect of mutant htt on the properties of rHD/G-DPSCs, the expression of mutant htt and the formation of oligomeric htt were evaluated. Expression of mutant htt was significantly increased in all HD-DPSCs determined by Q-PCR (Figure 4A). Among HD-DPSC lines, rHD17 had the highest expression of mutant *htt*, while rHD11 has the lowest (Figure 4A). The formation of mutant htt aggregate was revealed by using western blotting analysis (Figure 4B) and immunostaining (Figure 4C) using mEM48, a monoclonal antibody that binds to human htt enhanced with a polyQ expansion. Nuclear inclusions and mutant htt aggregates were observed in all rHD/G-DPSCs, but not in rG-DPSCs (Figure 4C). Among the three HD monkeys, rHD17 had the most extensive intranuclear inclusions and cytoplasmic mutant htt aggregates compared to rHD11 and rHD18. Western blotting analysis further confirmed the presence of oligomeric htt at a high molecular weight (> 250 kD) in the upper portion of a gradient polyacrylamide gel (Figure 4C) in all HD-DPSC cell lines. Again, rHD17 had a more intense band than rHD11 and rHD18, suggesting the presence of more oligomeric htt. The observation of htt by immunostaining of rHD/G-DPSCs was consistent with the expression level of mutant htt determined by Q-PCR and the extent of oligomeric htt demonstrated by Western blot analysis.

Discussion

Latest advancements in therapeutic applications of ASC have driven our interest in evaluating a patient's own DPSCs as an alternative source for cell therapy. Although recent studies have demonstrated the differentiation potential of DPSCs toward neuronal lineage [5,6], in-depth characterization such as biofunctions *in vivo* will further determine the therapeutic potential of DPSC derived neural cells. While therapeutic applications of DPSCs in cell replacement therapy are at preliminary






Figure 1 Isolation, culture and differentiation of rHD/G-DPSCs. (A) Spindle and fibroblast-like cells were observed in rHD/G-DPSC culture (Left), rHD/G-DPSCs express GFP (center) and overlay image (right). (B) Osteogenic differentiation, (C) Adipogenic differentiation, and (D) Chondrogenic differentiation of rHD/G-DPSCs and rG-DPSCs. Osteogenic and adipogenic differentiation were demonstrated by three weeks induction followed by Alizarin Red S and Oil-Red O staining, respectively. Chondrogenic differentiation was demonstrated by four weeks induction followed by Alcian blue staining of cryosection.



stage, continued development in differentiation protocol and *in vivo* validation are important steps. Unlike cell replacement, endogenous stem cells are expected to divide and differentiate under the influence of the DPSC graft and the microenvironment [4,5,12].

In this study, HD-DPSCs were derived from teeth buds of miscarried HD monkeys and HD monkeys that died soon after birth. While the biofunctions of HD-DPSCs may vary from those derived from adult individuals, our findings suggested rHD/G-DPSCs retain properties comparable to ASCs [3,4,24,27]. Additionally, the impact of age on the biofunctions of DPSCs has not been fully addressed and it is important for determining future applications of DPSCs derived from individuals at



different ages. Although we speculate the biofunctions of DPSCs will not be impacted significantly by age, the derivation efficiency of DPSCs may vary due to the number of stem cells existed in the dental pulps. While the present study is aimed to determine if DPSCs with inherited genetic defect retain ASC properties, our future goal is to determine if DPSCs derived from living HD monkeys or patients can be used to derive neuronal

Table 1 Cell surface antigen profiles of ASCs derived from monkey, chimpanzee and human

	rHD/G-DPSCs	rDPSCs	hBMSCs	ChDPSCs [2]	rBMSCs [23]	hDPSCs [3]	hBMSCs [24]
CD14*	-	-	-	-	-	-	-
CD18	-	-	-	-	ND	ND	-
CD24	-	-	-	-	ND	ND	-
CD29	+	+	+	+	+	+	+
CD34*	-	-	-	-	-	-	-
CD44	+	+	+	+	ND	+	+
CD45*	-	-	-	-	-	-	-
CD59	+	+	+	+	ND	ND	+
CD73*	+	+	+	+	ND	ND	+
CD90*	+	+	+	+	+	ND	+
CD105*	+	+	+	+	ND	ND	+
CD150	-	-	-	-	ND	-	-
CD166	+	+	+	+	+	+	+

*Important markers for hBMSCs

ND-Not Determine

cell types for replacement therapy. Moreover, genetic correction of HD-DPSCs may be considered prior cell transplantation because HD-DPSCs may not have longevity and may not function in the same way as DPSCs derived from normal animals.

Multipotent differentiation capability was evaluated by *in vitro* differentiation into osteogenic, adipogenic and chondrogenic lineages. Differentiation into these three lineages is considered one of the basic requirements for BMSCs, which is widely applied in ASCs [24]. All rHD/G-DPSCs differentiated to osteogenic, adipogenic and chondrogenic lineages, which were comparable to rG-DPSCs and published reports (Figure 1) [2-4,27,28]. Recent studies have suggested that DPSCs are also capable of differentiating into neurons [5,6,8,29]. Although the current paradigm of ASC therapy is primarily based on the homing nature of ASCs [12,30,31] and their capability of eliciting a local repair response [4,12,30,32], their ability to differentiate into multiple cell types including neurons may be therapeutically relevant. While all tested cell lines were capable of differentiating into three different lineages, quantitative studies on specific lineage markers suggested variations in differentiation capacity among DPSC cell lines exists. Therefore, whether DPSCs derived from HD monkeys or normal rhesus monkeys have more preferred lineages upon differentiation cannot be concluded.

Conclusions

Our results suggested that DPSCs derived from HD monkeys retain ASC properties, thus one may consider that these cells also retain biofunctions comparable to those derived from healthy individuals [4]. This study

supports the potential future therapeutic application of DPSCs from patients with genetic disorders such as HD. We demonstrated that DPSCs from HD monkeys are comparable in all aspects that define ASCs. Thus DPSCs derived from patients with inherited genetics diseases hold great promise as an alternative source for personal cell therapy.

Methods


All transgenic HD monkeys were housed under the guideline of the IACUC approved procedures and the support of the Division of Animal Resources at the Yerkes National Primate Research Center (YNPRC). All procedures were approved by YNPRC/Emory Animal Care and Biosafety Committees.

Generation of transgenic monkeys [22]

Transgenic Huntington's monkeys were generated as described by Yang and colleagues [22]. In brief, lentiviruses carrying the Exon 1 of the htt gene containing expanded CAGs under the control of ubiquitin promoter were used to infect metaphase II arrested rhesus monkey oocytes followed by fertilization and embryo transfer into surrogate females.

Isolation and culture of DPSCs [4,25]

The teeth germs/buds were recovered from monkeys miscarried at four months gestation (rHD11 and rGFP) and died soon after birth (rHD17 and rHD18). The teeth germs/buds were then digested in 3 mg/ml collagenase type I and 4 mg/ml dispase (Invitrogen, Inc) for one hour at 37°C. Single cell suspension was filtered through a 70 µm cell strainer and was then cultured in



DPSC culture medium (α -MEM (Invitrogen, Inc) supplemented with 20% FBS (Atlanta Biologicals, Inc), 2 mM glutamine, 100 units/ml penicillin and 100 μ g/ml streptomycin (Invitrogen, Inc.)) at 37°C with 5%CO₂.

Adipogenic, osteogenic and chondrogenic differentiation [2,4,25]

For adipogenic differentiation, cells were seeded at 400 cells/35 mm tissue culture dish and cultured for 11 days in DPSC medium. On day 11, the medium was supplemented with 5.0 μ g/ml insulin, 50 μ M indomethacin, 1 μ M dexamethasone, and 0.5 μ M IBMX, which was replaced every 3-4 days for a total of three weeks. The culture was then fixed in 4% paraformaldehyde (PFA) and stained with 0.0125% Oil-Red-O in isopropanol for 20 minutes at RT followed by a thorough wash and microscopic examination.

For osteogenic differentiation, cells were prepared as described for adipogenic differentiation until day 11. On day 11, the medium was supplemented with 1 nM dexamethasone, 50 μ M L-Ascorbic acid 2-phosphate sesquimagnesium salt, 20 mM β -glycerolphosphate, and 50 ng/ml L-thyroxine sodium pentahydrate, and was replaced every 3-4 days for a total of three weeks. The culture was then fixed in 4% PFA and stained with 1% Alizarin Red S, pH 4.1 for 20 minutes at RT followed by a thorough wash and microscopic examination.

For chondrogenic differentiation, 2.5×10^5 DPSCs were centrifuged in a 15 ml conical tube at 1,000 rpm for five minutes. The pellet was maintained in a DPSC medium supplemented with ITS-plus premix (BD Biosciences) to a final concentration of 6.25 μ g/ml insulin, 6.25 μ g/ml transferrin, and 6.25 ng/ml selenious acid. Additionally, 5.35 μ g/ml linoleic acid, 1.25 mg/ml bovine serum albumin, 50 μ g/ml Ascorbate 2-phosphate, 40 μ g/ml L-proline, 100 μ g/ml Sodium pyruvate, 100 nM Dexamethasone, 100 units/ml penicillin, 100 μ g/ml streptomycin and 10 ng/ml TGF- β 3 (R&D Systems) were also supplemented. Medium was replaced every 3-4 days for a total of four weeks. The pellets were then fixed in 4% PFA overnight. The paraffin-embedded sections (4-5 μ m) were stained with 1% Alcian blue in 10% sulphuric acid solution for 15 minutes followed by a thorough wash and microscopic examination.

Quantitative Real-Time PCR (Q-PCR)

RNA from cell samples was prepared using RNeasy Mini kit (Qiagen). An equal amount of total RNA was used to synthesize cDNA followed by Q-PCR using iQ5 Real-Time PCR Detection System (Bio-Rad). Specific-qPCR primer sets targeting stem cell and differentiation markers were used (Additional file 1).

Immunocytochemistry and fluorescent microscopy [22]

Cell samples were fixed using 4% PFA, permeabilized and blocked. The expression of mutant htt was then incubated with mEM48. The mEM48 (1:200) immunoreactive product was visualized with the avidin-biotin complex kit (Vector ABC Elite). For fluorescent microscopy, the samples were examined with an Olympus BX51 epifluorescent microscope.

Western Blotting [22]

Total protein was extracted and concentrated for analysis using the Bradford Assay (Bio-Rad, Inc.). Equal amounts of the protein were boiled prior to polyacrylamide gel electrophoresis, the proteins were transferred onto a PVDF membrane (Millipore Immobion P, Millipore, Inc.) using Bio-Rad's transblot. The membrane was then blocked, incubated with primary antibody, secondary antibody, and detected using Amersham's ECL kit (Amersham, Inc.). The amount of protein was quantified using a densitometer.

Flow cytometry analysis [2,4]

Cell samples at 2×10^5 cells/tube were stained with FITC or PE-conjugated anti-CD14, -CD45, -CD59, -CD73, -CD90, -CD150, -CD166, -IgG1k, -IgG2ak (BD Pharmingen), or anti-CD18, -CD24, -CD29, -CD34, -CD44 (BD Biosciences), or anti-CD105 (eBioscience). After incubating 20 minutes at RT in the dark, cells were washed with 2 mL FACS wash solution (dPBS+1%BSA+0.1%Na₃) and centrifuged five minutes at $230 \times g$. Supernatant was removed and cells were fixed with 1% formaldehyde. All data was acquired using a FACS Calibur (Becton Dickinson) and analyzed using CellQuest (Becton Dickinson) and Flowjo software (Treestar, Inc.).

Statistical analysis

Data analyses were carried out using the *Student t*-test.

Additional material

Additional file 1: Supplemental Methods. Primer sets for stemness and differentiation markers.

Acknowledgements

We thank Dimitri Fillos and Dr. Chris C. Ibegbu for their assistance in flow cytometry analysis. We also thank Dr. XJ Li for mEM48. All protocols involving animal care and handling were approved by Emory University's IACUC. Yerkes National Primate Research Center is supported by the base grant No.RR-00165 awarded by the NCCR/NIH. This study is supported by grant awarded by the NCCR/NIH (RR018827-04). The authors have no commercial association that might create a conflict of interest in connection with submitted manuscript.

Author details

¹Yerkes National Primate Research Center, 954 Gatewood Rd., N.E. Atlanta, GA 30329, USA. ²Department of Human Genetics, Emory University School of Medicine, 615 Michael St. Whitehead Building, Atlanta, GA 30322, USA.

³Department of Oral Pathology, School of Dentistry, Kaohsiung Medical University, 100 Shih-Chuan 1st Road, Kaohsiung, Taiwan, Republic of China.

Authors' contributions

BRS, PHC: DPSCs culture, in vitro differentiation, molecular analysis; JJY: DPSCs derivation and culture; SHY: Histological analysis; AHCH: DPSCs derivation and conceptual design; AWS: DPSCs derivation, in vitro differentiation, conceptual design, preparation and approval of manuscript. All authors have read and approved the final manuscript.

Received: 10 June 2011 Accepted: 12 September 2011

Published: 12 September 2011

References

1. Gronthos S, Brahimi J, Li W, Fisher LW, Cherman N, Boyde A, DenBesten P, Robey PG, Shi S: **Stem cell properties of human dental pulp stem cells.** *Journal of dental research* 2002, **81**(8):531-535.
2. Cheng PH, Snyder B, Fillos D, Ibegbu CC, Huang AH, Chan AW: **Postnatal stem/progenitor cells derived from the dental pulp of adult chimpanzee.** *BMC cell biology* 2008, **9**:20.
3. Gronthos S, Mankani M, Brahimi J, Robey PG, Shi S: **Postnatal human dental pulp stem cells (DPSCs) in vitro and in vivo.** *Proceedings of the National Academy of Sciences of the United States of America* 2000, **97**(25):13625-13630.
4. Huang AH, Snyder BR, Cheng PH, Chan AWS: **Putative dental pulp derived stem/stromal cells promote proliferation and differentiation of endogenous neural cells in the hippocampus of mice.** *Stem cells (Dayton, Ohio)* 2008, **26**:2654-2663.
5. Arthur A, Rychkov G, Shi S, Koblar SA, Gronthos S: **Adult human dental pulp stem cells differentiate toward functionally active neurons under appropriate environmental cues.** *Stem cells (Dayton, Ohio)* 2008, **26**(7):1787-1795.
6. Arthur A, Shi S, Zannettino AC, Fujii N, Gronthos S, Koblar SA: **Implanted adult human dental pulp stem cells induce endogenous axon guidance.** *Stem cells (Dayton, Ohio)* 2009, **27**(9):2229-2237.
7. Kiraly M, Kadar K, Horvath DB, Nardai P, Racz GZ, Lacza Z, Varga G, Gerber G: **Integration of neuronally predifferentiated human dental pulp stem cells into rat brain in vivo.** *Neurochem Int* 2011.
8. Kiraly M, Porcsalmy B, Pataki A, Kadar K, Jelitai M, Molnar B, Hermann P, Gera I, Grimm WD, Ganss B, et al: **Simultaneous PKC and cAMP activation induces differentiation of human dental pulp stem cells into functionally active neurons.** *Neurochem Int* 2009, **55**(5):323-332.
9. Nesti C, Pardini C, Barachini S, D'Alessandro D, Siciliano G, Murri L, Petrini M, Vaglini F: **Human dental pulp stem cells protect mouse dopaminergic neurons against MPP+ or rotenone.** *Brain research* 2011, **1367**:94-102.
10. Yalvac ME, Ramazanoglu M, Rizvanov AA, Sahin F, Bayrak OF, Salli U, Palotas A, Kose GT: **Isolation and characterization of stem cells derived from human third molar tooth germs of young adults: implications in neo-vascularization, osteo-, adipo- and neurogenesis.** *Pharmacogenomics J* 2010, **10**(2):105-113.
11. Nosrat IV, Smith CA, Mullally P, Olson L, Nosrat CA: **Dental pulp cells provide neurotrophic support for dopaminergic neurons and differentiate into neurons in vitro; implications for tissue engineering and repair in the nervous system.** *The European journal of neuroscience* 2004, **19**(9):2388-2398.
12. Munoz JR, Stoutenger BR, Robinson AP, Spees JL, Prockop DJ: **Human stem/progenitor cells from bone marrow promote neurogenesis of endogenous neural stem cells in the hippocampus of mice.** *Proceedings of the National Academy of Sciences of the United States of America* 2005, **102**(50):18171-18176.
13. Arora V, Arora P, Munshi AK: **Banking stem cells from human exfoliated deciduous teeth (SHED): saving for the future.** *J Clin Pediatr Dent* 2009, **33**(4):289-294.
14. Woods EJ, Perry BC, Hockema JJ, Larson L, Zhou D, Goebel WS: **Optimized cryopreservation method for human dental pulp-derived stem cells and their tissues of origin for banking and clinical use.** *Cryobiology* 2009, **59**(2):150-157.
15. Yalvac ME, Rizvanov AA, Kilic E, Sahin F, Mukhamedyarov MA, Islamov RR, Palotas A: **Potential role of dental stem cells in the cellular therapy of cerebral ischemia.** *Curr Pharm Des* 2009, **15**(33):3908-3916.

16. Yang KL, Chen MF, Liao CH, Pang CY, Lin PY: **A simple and efficient method for generating Nurr1-positive neuronal stem cells from human wisdom teeth (tNSC) and the potential of tNSC for stroke therapy.** *Cytotherapy* 2009, **11**(5):606-617.
17. Snell RG, MacMillan JC, Cheadle JP, Fenton I, Lazarou LP, Davies P, MacDonald ME, Gusella JF, Harper PS, Shaw DJ: **Relationship between trinucleotide repeat expansion and phenotypic variation in Huntington's disease.** *Nature genetics* 1993, **4**(4):393-397.
18. Andrew SE, Goldberg YP, Kremer B, Telenius H, Theilmann J, Adam S, Starr E, Squitieri F, Lin B, Kalchman MA, et al: **The relationship between trinucleotide (CAG) repeat length and clinical features of Huntington's disease.** *Nature genetics* 1993, **4**(4):398-403.
19. Sapp E, Schwarz C, Chase K, Bhide PG, Young AB, Penney J, Vonsattel JP, Aronin N, DiFiglia M: **Huntingtin localization in brains of normal and Huntington's disease patients.** *Annals of neurology* 1997, **42**(4):604-612.
20. Bradford H, Britto LR, Leal G, Katz J: **Endodontic treatment of a Patient with Huntington's disease.** *Journal of endodontics* 2004, **30**(5):366-369.
21. Jackowski J, Andrich J, Kappeler H, Zollner A, Johren P, Muller T: **Implant-supported denture in a patient with Huntington's disease: interdisciplinary aspects.** *Spec Care Dentist* 2001, **21**(1):15-20.
22. Yang SH, Cheng PH, Banta H, Piotrowska-Nitsche K, Yang JJ, Cheng EC, Snyder B, Larkin K, Liu J, Orkin J, et al: **Towards a transgenic model of Huntington's disease in a non-human primate.** *Nature* 2008, **453**(7197):921-924.
23. Izadpanah R, Joswig T, Tsien F, Dufour J, Kirijan JC, Bunnell BA: **Characterization of multipotent mesenchymal stem cells from the bone marrow of rhesus macaques.** *Stem cells and development* 2005, **14**(4):440-451.
24. Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, Deans R, Keating A, Prockop D, Horwitz E: **Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement.** *Cytotherapy* 2006, **8**(4):315-317.
25. Huang AHC, Chan YK, Lin ML, Shieh TY, Chan AWS: **Isolation and characterization of dental pulp stem cells from supernumerary tooth.** *Journal of Oral Pathology & Medicine* 2008, **37**(9):571-574.
26. Prockop DJ: **Marrow stromal cells as stem cells for nonhematopoietic tissues.** *Science* 1977, **276**:71-74.
27. Pierdomenico L, Bonsi L, Calvitti M, Rondelli D, Arpinati M, Chirumbolo G, Becchetti E, Marchionni C, Alviano F, Fossati V, et al: **Multipotent mesenchymal stem cells with immunosuppressive activity can be easily isolated from dental pulp.** *Transplantation* 2005, **80**(6):836-842.
28. Laino G, d'Aquino R, Graziano A, Lanza V, Carinci F, Naro F, Pirozzi G, Papaccio G: **A new population of human adult dental pulp stem cells: a useful source of living autologous fibrous bone tissue (LAB).** *J Bone Miner Res* 2005, **20**(8):1394-1402.
29. Iohara K, Zheng L, Ito M, Tomokiyo A, Matsushita K, Nakashima M: **Side population cells isolated from porcine dental pulp tissue with self-renewal and multipotency for dentinogenesis, chondrogenesis, adipogenesis, and neurogenesis.** *Stem cells (Dayton, Ohio)* 2006, **24**(11):2493-2503.
30. Laino G, Graziano A, d'Aquino R, Pirozzi G, Lanza V, Valiante S, De Rosa A, Naro F, Vivarelli E, Papaccio G: **An approachable human adult stem cell source for hard-tissue engineering.** *Journal of cellular physiology* 2006, **206**(3):693-701.
31. Ohtaki H, Ylostalo JH, Foraker JE, Robinson AP, Reger RL, Shioda S, Prockop DJ: **Stem/progenitor cells from bone marrow decrease neuronal death in global ischemia by modulation of inflammatory/immune responses.** *Proceedings of the National Academy of Sciences of the United States of America* 2008, **105**(38):14638-14643.
32. Lee RH, Seo MJ, Reger RL, Spees JL, Pulin AA, Olson SD, Prockop DJ: **Multipotent stromal cells from human marrow home to and promote repair of pancreatic islets and renal glomeruli in diabetic NOD/scid mice.** *Proceedings of the National Academy of Sciences of the United States of America* 2006, **103**(46):17438-17443.

doi:10.1186/1471-2121-12-39

Cite this article as: Snyder et al.: Characterization of dental pulp stem/stromal cells of Huntington monkey tooth germs. *BMC Cell Biology* 2011 **12**:39.

Submit your next manuscript to BioMed Central and take full advantage of:

- **Convenient online submission**
- **Thorough peer review**
- **No space constraints or color figure charges**
- **Immediate publication on acceptance**
- **Inclusion in PubMed, CAS, Scopus and Google Scholar**
- **Research which is freely available for redistribution**

Submit your manuscript at
www.biomedcentral.com/submit

